Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

Axogen (AXGN) announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Bishop will report to Michael Dale, President, ...

Mr. Bishop has over 13 years of leadership experience in regulatory strategy, planning and execution in companies such as Thermo Fisher Scientific – Viral Vector Services, RGI Medical Manufacturing, ...

For a moment during his first term as president, he had a positive job-approval ratio, but it went south by February 3, 2017, and never recovered. On Election Day 2020, his job-approval numbers ...

According to a national study conducted by Emerson College Polling, President Trump has started his term with a 49% approval rating. He also got a 41% disapproval rate, while 10% are neutral.

VectorBuilder' s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S ...

This enables enhanced immunity in a safe and efficient way, exemplified by Jcovden, a single-dose adenovirus vector-based vaccine, granted approval for emergency use after safety and efficacy ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

The beginning of President Donald Trump's second term has seen his net approval rating reach a historic high, according to Rasmussen Reports, with the latest Presidential Tracking Poll showing a ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...